Despite the growing interest in circulating cell-free DNA (cfDNA), no conclusive evidence exists on the value of quantitative analysis of cfDNA for the prediction of lung cancer survival. We performed a systematic review and meta-analysis of primary studies to estimate the impact of higher baseline cfDNA levels on survival outcomes of patients with lung cancer
Background: Circulating DNA is observed at higher concentrations in patients with lung cancer than i...
DNA in plasma/serum is a promising noninvasive diag-nostic and prognostic tool requiring only a bloo...
BackgroundThe overall aim was to investigate the change over time in circulating cell free DNA (cfDN...
Despite the growing interest in circulating cell-free DNA (cfDNA), no conclusive evidence exists on ...
INTRODUCTION: Circulating plasma DNA is present in a considerably higher concentration in lung cance...
Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are promising prognostic and predictive bio...
Abstract Background Plasma circulating cell-free (cf) DNA is regarded as a source of tumor DNA. Base...
Background: Non-small cell lung cancer (NSCLC) is leading cause of cancer related death and the surv...
Abstract Background Some research found that elevated plasma cell-free DNA (cfDNA) concentrations an...
We retrospectively assessed prognostic value of circulating cell-free DNA (cfDNA) using data from th...
Background: Despite the increasing implementation of targeted and immunotherapy-based treatments, th...
Background: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of...
BACKGROUND: The overall aim was to investigate the change over time in circulating cell free DNA (cf...
PURPOSE: Analysis of circulating DNA in plasma can provide a useful marker for earlier lung cancer d...
Background: Increased presence of circulating DNA has been reported in lung cancer. However, the uti...
Background: Circulating DNA is observed at higher concentrations in patients with lung cancer than i...
DNA in plasma/serum is a promising noninvasive diag-nostic and prognostic tool requiring only a bloo...
BackgroundThe overall aim was to investigate the change over time in circulating cell free DNA (cfDN...
Despite the growing interest in circulating cell-free DNA (cfDNA), no conclusive evidence exists on ...
INTRODUCTION: Circulating plasma DNA is present in a considerably higher concentration in lung cance...
Cell-free DNA (cfDNA) and circulating tumor cells (CTCs) are promising prognostic and predictive bio...
Abstract Background Plasma circulating cell-free (cf) DNA is regarded as a source of tumor DNA. Base...
Background: Non-small cell lung cancer (NSCLC) is leading cause of cancer related death and the surv...
Abstract Background Some research found that elevated plasma cell-free DNA (cfDNA) concentrations an...
We retrospectively assessed prognostic value of circulating cell-free DNA (cfDNA) using data from th...
Background: Despite the increasing implementation of targeted and immunotherapy-based treatments, th...
Background: Non-small cell lung cancer (NSCLC) often presents at an incurable stage, and majority of...
BACKGROUND: The overall aim was to investigate the change over time in circulating cell free DNA (cf...
PURPOSE: Analysis of circulating DNA in plasma can provide a useful marker for earlier lung cancer d...
Background: Increased presence of circulating DNA has been reported in lung cancer. However, the uti...
Background: Circulating DNA is observed at higher concentrations in patients with lung cancer than i...
DNA in plasma/serum is a promising noninvasive diag-nostic and prognostic tool requiring only a bloo...
BackgroundThe overall aim was to investigate the change over time in circulating cell free DNA (cfDN...